Piper Sandler raised the firm’s price target on Health Catalyst (HCAT) to $12 from $11 and keeps an Overweight rating on the shares after updating the firm’s model to reflect revised calendar year 2024 guidance and the company’s expectation for year-over-year adjusted EBITDA growth of about 50% next year. The firm notes its new target reflects an unchanged multiple applied to its higher calendar 2025 adjusted EBITDA estimate.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT:
- Health Catalyst price target raised to $9 from $7 at Stephens
- Health Catalyst price target raised to $10.50 from $9 at Citi
- Health Catalyst Reports Q3 Revenue Growth Amid Reduced Losses
- Health Catalyst announces partnership with CyncHealth
- Health Catalyst to acquire Intraprise Health, terms not disclosed